Experimental PPAR-delta agonist · Fact sheet
GW501516
Also known as Cardarine · GW1516 · Endurobol
GW501516, commonly called cardarine, is a PPAR-delta agonist, not a SARM or peptide. Human lipid-marker effects do not establish safe endurance or fat loss; development ended after serious preclinical toxicities.
What is GW501516?
PPAR-delta is a nuclear receptor involved in metabolic gene regulation.
Sharing performance-related marketing with SARMs does not make this an androgen-receptor drug.
Benefits & claims
Interest includes performance or metabolic effects, but a mechanism, hormone change or lean-mass result does not establish safe improvement in athletic function.
What the evidence supports
- A 268-person trial changed several lipid measures over 12 weeks.
- That trial did not establish fewer heart attacks, longer life or safe athletic enhancement.
- A favorable lipid profile cannot cancel unresolved serious toxicology findings.
Research areas
- Performance-related biology
- Clinical or preclinical disease research
Dosage & frequency
No established human regimenThe reviewed sources do not establish a human treatment amount or frequency for GW501516. Animal and laboratory exposures are not human regimens.
How to read these amounts
An approved regimen belongs to a specific product, indication, and population. A study regimen describes what researchers tested; it does not establish a prescription or a safe self-use protocol. Products, routes, and formulations are not interchangeable. A prescriber uses the full label and individual clinical circumstances.
Personal accounts may describe amounts, schedules and outcomes beyond clinical research. They do not establish a regimen. Read the reported experiences
Formulations, interactions & practical context
- Identity and pharmacology
- PPAR-delta is a nuclear receptor involved in metabolic gene regulation.
Formulation differences
- Sharing performance-related marketing with SARMs does not make this an androgen-receptor drug.
Interactions & precautions
- The reviewed sources do not establish a comprehensive human interaction profile for this exact substance or combination.
What is still unresolved
- Long-term clinically meaningful benefit
- Endocrine, cardiovascular and organ safety
- Identity, exposure and interaction differences outside research settings
Side effects & risks
- WADA issued an unusual safety alert after serious toxicities ended development.
- The human relevance and magnitude of long-term risks cannot be resolved by short biomarker trials.
This is a summary of the cited evidence, not a complete product label. A lack of human safety data does not establish safety.
Clinical research
Limited or unclear evidenceHuman studies evaluated lipid markers, while the safety alert concerns serious preclinical toxicities and terminated pharmaceutical development. Biomarker changes do not establish cardiovascular-event benefit.
Studies
268-person 12-week lipid-marker trial.
Preclinical hepatic-stellate-cell and fibrosis findings.
Personal experiences
Reports describe what someone noticed. They cannot establish cause, typical results, or how often a side effect happens. Amounts and schedules describe the individual account, not an effective or safe dose. Product identity and strength may be unverified, and missing details are left explicit.
No attributable personal accounts were found in the sources reviewed.
Approval status
GW501516 has no FDA-approved product. WADA reports that pharmaceutical development was terminated after serious preclinical toxicities; independent laboratory research is not regulatory approval.
Referenced development program stopped
Approval covers the labeled product, use and population. A trial phase does not establish success; a stopped program is not ongoing research.
- Lipid effects of peroxisome proliferator-activated receptor-δ agonist GW501516 in subjects with low high-density lipoprotein cholesterol: characteristics of metabolic syndrome.
- GW501516-activated PPARβ/δ promotes liver fibrosis via p38-JNK MAPK-induced hepatic stellate cell proliferation.
- WADA primary GW501516 safety alert
Open questions
- Long-term clinically meaningful benefit
- Endocrine, cardiovascular and organ safety
- Identity, exposure and interaction differences outside research settings
Summary
A favorable lipid profile cannot cancel unresolved serious toxicology findings.
Sources
Medical evidence and regulatory sources are listed here. Personal reports are linked separately in the experiences section.
- pubmedLipid effects of peroxisome proliferator-activated receptor-δ agonist GW501516 in subjects with low high-density lipoprotein cholesterol: characteristics of metabolic syndrome.
268-person 12-week lipid-marker trial.
- pubmedGW501516-activated PPARβ/δ promotes liver fibrosis via p38-JNK MAPK-induced hepatic stellate cell proliferation.
Preclinical hepatic-stellate-cell and fibrosis findings.
- medical institutionWADA primary GW501516 safety alert
WADA document hosted by FIA; states development ended after serious preclinical toxicities.